# A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor

Source: https://onco.cc/trials/nct03314181/  
OnCo record `nct03314181` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dexamethasone, Daratumumab, Venetoclax in multiple myeloma, run by AbbVie, active and no longer recruiting.

## Summary

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT03314181 by AbbVie, with 156 participants enrolled, started 2018-04-02 and due to reach its primary completion in 2031-05. Interventions recorded: Dexamethasone, Daratumumab, Venetoclax, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03314181
- Phase: 2
- Setting: A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
- Sponsor: AbbVie
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT03314181: https://clinicaltrials.gov/study/NCT03314181

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct03314181.json